Correspondence | Published:

‘To treat or not to treat’: raising awareness on the effects of graft versus host disease drugs on musculoskeletal system

Bone Marrow Transplantationvolume 53pages909912 (2018) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–33.

  2. 2.

    Flowers MED, Vogelsang GB. Clinical manifestations and natural history. In: Vogelsang GB, Pavletic SZ (eds). Chronic Graft Versus Host Disease: Interdisciplinary Management. New York, NY, USA: Cambridge University Press; 2009. pp 56–69.

  3. 3.

    Mohammed J, Savani B, El-Jawahri A, Vanderklish J, Cheville A, Hashmi S. Is there any role for physical therapy in chronic GvHD?. Bone Marrow Transplant. 2018;53:22–28.

  4. 4.

    Holler E. Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment. Best Pract Res Clin Haematol. 2007;20:281–94.

  5. 5.

    Fujii N, Ikeda K, Koyama M, Aoyama K, Masunari T, Kondo E, et al. Calcineurininhibitor—induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantatioan. Int J Hematol. 2006;83:459–61.

  6. 6.

    Collini A, De Bartolomeis C, Barni R, Ruggieri G, Bernini M, Carmellini M. Calcineurin-inhibitor induced pain syndrome after organ transplantation. Kidney Int. 2006;70:1367–70.

  7. 7.

    Naredo SE, Balsa CA, Sanz GA, Pantoja ZL, Martín ME, Gijón BJ. Leg bone pain syndrome due to cyclosporine in a renal transplant patient. Clin Exp Rheumatol. 1993;12:653–6.

  8. 8.

    Van Lint MT, Milone G, Leotta S, Uderzo C, Scime R, Dallorso S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day+ 5 responders and no advantage for nonresponders receiving anti–thymocyte globulin. Blood. 2006;107:4177–81.

  9. 9.

    Dignan FL, Amrolia P, Clark A, Cornish J, Jackson G, Mahendra P, et al. Diagnosis and management of chronic graft‐versus‐host disease. Br J Haematol. 2012;158:46–61.

  10. 10.

    Gergis U, Markey K, Greene J, Kharfan-Dabaja M, Field T, Wetzstein G, et al. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant. 2010;45:662–7.

  11. 11.

    Balasubramanian A, Wade SW, Adler RA, Lin CJ, Maricic M, O’Malley CD, et al. Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int. 2016;27:3239–49.

  12. 12.

    Li X, Brazauskas R, Wang Z, Al-Seraihy A, Baker KS, Cahn JY, et al. Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents. Biol Blood Marrow Transplant. 2014;20:587–92.

  13. 13.

    Montalbano M, Neff GW, Yamashiki N, Meyer D, Bettiol M, Slapak-Green G, et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation. 2004;78:264–8.

  14. 14.

    Stallone G, Infante B, Grandaliano G, Gesualdo L. Management of side effects of sirolimus therapy. Transplantation. 2009;87(8S):S23–6.

  15. 15.

    Xu SL, Zhang YC, Wang GY, Yang Q, Liu B, Zhang J, et al. Survival analysis of sirolimus-based immunosuppression in liver transplantation in patients with hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2016;40:674–81.

  16. 16.

    Merin NM, Kelly KR. Clinical use of proteasome inhibitors in the treatment of multiple myeloma. Pharmaceuticals. 2016;8:1–20.

  17. 17.

    Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012;26:595–608.

  18. 18.

    Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24:3113–20.

  19. 19.

    Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol. 2014;32:634–40.

  20. 20.

    Humpel N, Iverson DC. Review and critique of the quality of exercise recommendations for cancer patients and survivors. Support Care Cancer. 2005;13:493–502.

  21. 21.

    Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. New Engl J Med. 2015;372:426–35.

  22. 22.

    Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012;119:4614–8.

  23. 23.

    Harrison C, Mesa R, Ross D, Mead A, Keohane C, Gotlib J, et al. Practical management of patients with myelofibrosis receiving ruxolitinib. Expert Rev Hematol. 2013;6:511–23.

  24. 24.

    Dahl K, Battisti JL. CNS demyelination during Anti TNF-alpha therapy (P4. 067). Neurology. 2015;84:P4–067.

  25. 25.

    Rupasree Y, Naushad SM, Rajasekhar L, Uma A, Kutala VK. Association of TLR4 (D299G, T399I), TLR9− 1486 T > C, TIRAP S180L and TNF-α promoter (− 1031,− 863,− 857) polymorphisms with risk for systemic lupus erythematosus among South Indians. Lupus. 2015;24:50–7.

  26. 26.

    Psarelis S, Hajineocli AP, Hadjicosta E, Elliott HS, Johnson P. Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barré syndrome after anti-TNF-α treatment? Case report and literature review. Clin Rheumatol. 2017;36:1197–9.

  27. 27.

    Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA. Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther. 2014;16:R125.

  28. 28.

    Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2012;31:88–94.

  29. 29.

    Sarcon A, Botta GP, Patel N, Saven A. Spontaneous iliopsoas muscle hemorrhage secondary to ibrutinib (Imbruvica; Pharmacyclics) brief report. J Invest Med High Impact case Rep. 2016;4:2324709616648457.

Download references

Author contributions

JM, TA, and SKH wrote the first draft of the manuscript. All authors contributed substantially to the conception, acquisition, analysis, and interpretation of the data for the work.

Author information

Author notes

  1. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the US Army or US Department of Defence.

Affiliations

  1. Department of Physical Therapy and Rehabilitation, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

    • Jaleel Mohammed
  2. Physical Therapy Association for Graft Versus Host Disease, Swindon, UK

    • Jaleel Mohammed
  3. MSU-E, US Army, Kaiserslautern, Germany

    • Tola Akomolafe
  4. Department of Adult Hematology and Stem Cell Transplant, King Faisal Hospital and Research Center, Riyadh, Saudi Arabia

    • Mahmoud Aljurf
    •  & Shahrukh K. Hashmi
  5. Department of Medicine, Vanderbilt University, Nashville, TN, USA

    • Bipin Savani
  6. Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

    • Shahrukh K. Hashmi

Authors

  1. Search for Jaleel Mohammed in:

  2. Search for Tola Akomolafe in:

  3. Search for Mahmoud Aljurf in:

  4. Search for Bipin Savani in:

  5. Search for Shahrukh K. Hashmi in:

Conflicts of interest

There are no conflicts of interest to disclose from any authors.

Corresponding author

Correspondence to Jaleel Mohammed.

About this article

Publication history

Received

Revised

Accepted

Published

Issue Date

DOI

https://doi.org/10.1038/s41409-018-0095-7